Certified by Founder
Lodge
Delphia Therapeutics
start up
United States
- Cambridge, Massachusetts
- 07/05/2024
- Series A
- $67,000,000
Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.
- Industry Biotechnology Research
- Website https://www.delphiatx.com/
- LinkedIn https://www.linkedin.com/company/delphia-therapeutics/
NuCube Energy | $13,000,000 | (Feb 20, 2026)
Vizzia | $35,300,400 | (Feb 20, 2026)
PolyGone Systems Inc | $4,000,000 | (Feb 20, 2026)
Altesa BioSciences, Inc. | $75,000,000 | (Feb 20, 2026)
Eagle Wireless | $30,000,000 | (Feb 20, 2026)
Stacks | $23,000,000 | (Feb 20, 2026)
SPRX | $31,000,000 | (Feb 20, 2026)
Adronite | $5,000,000 | (Feb 20, 2026)
Odynn | $9,500,000 | (Feb 20, 2026)
Ascent(US) | $45,000,000 | (Feb 20, 2026)
Ownwell | $50,000,000 | (Feb 20, 2026)
Badge | $17,100,000 | (Feb 20, 2026)